From partnership preparation in Shanghai to the completion of our flagship base in Dhaka, Bangladesh — eight years from multinational preparation to an in-house GMP manufacturing base.
About FLAB
A life-science group built for scale
Driven by quality and innovation, FLAB Integrated Pharmaceutical Group is building one of the life-science manufacturing networks spanning Southeast and East Asia, producing medicines, biopharmaceuticals, cosmetics, home and hygiene products, and chemicals to international standards.
Quality of life is life itself.Large-scale production across 12 specialized workshops, backed by a simple belief — products reach clinics and pharmacies in every province.
4Countries with warehouse nodes
12Specialized production units
300+Employees
$270MCompany assets (USD)
Milestones
Our development journey
The nodes below are compiled from official history materials, with key certification and capacity milestones marked.
March 2017Shanghai, China
Strategic partnership with a leading domestic pharmaceutical company; a multinational pharmaceutical project preparation team was established.
August 2018Dhaka, Bangladesh
The Bangladesh joint venture was formally established, launching local market research and drug registration.
December 2019Chattogram, BangladeshFirst GMP workshop
Acquired a small local pharmaceutical plant and built the first GMP-compliant solid dosage workshop.
June 2020Jiangsu, China
Established the pharmaceutical intermediate and API R&D center, enabling an integrated “raw material + formulation” footprint.
2021–2022Dhaka, BangladeshManufacturing license
Phase I of the Dhaka pharmaceutical plant started construction in 2022; main works and equipment commissioning were completed in 2023, and a manufacturing license was issued by Bangladesh DGDA.
May 2022Dhaka, BangladeshSterile injectables online
The group’s first sterile injectable workshop entered production, filling the local gap in high-end antibiotic injectables.
February 2023Geneva, SwitzerlandWHO prequalification (PQ)
Our core antimalarial formulation obtained WHO prequalification (PQ), qualifying for international procurement.
June 2023Dhaka, BangladeshFlagship base launched
Invested in the group’s flagship pharmaceutical base in South Asia.
Construction of the flagship plant began in 2023 and was completed in 2025. Upon completion it comprises 200,000 m² of modern infrastructure, 12 production units (oral solid dosage, sterile injectables and biologics) and 20 automated packaging lines.
What We Do
What we do
Peptides
Research-grade lyophilized peptide powders, 99%+ purity, CoA included with independent HPLC / MS verification. Four directions: metabolic & weight management, growth hormone & repair, recovery, and cosmetic & skin.
Finished medicines
The group supplies marketed finished medicines, including targeted oncology and gene therapy products, to overseas markets only.
Manufacturing & fulfillment
The Bangladesh manufacturing base handles production and quality control, with delivery through warehouse nodes in the US, UK, Australia and Bangladesh.
Capacity
Flagship base capacity
Flagship plant in the Savar industrial zone, completed in 2025.
